DVLP is building a new infrastructure for drug development by digitizing drug assets, financing, and development workflows to accelerate the process of turning molecules into medicines.

DVLP

Turbine develops a platform called Simulated Cell™ to simulate biological experiments prior to execution, aimed at enhancing drug development efficiency and accuracy.

Turbine

Ablynx develops NANOBODY® technology, which enables the creation of new therapeutics and the refinement of existing treatments. The technology utilizes miniature, engineered antibodies derived from camelids, allowing for the design of multi-targeting therapies.

Ablynx

Benchling is a biology-first platform for scientific data, collaboration, and insights, dedicated to accelerating R&D and driving impact in the biotech industry.

Benchling

DVLP is focused on creating a new infrastructure for drug development by digitizing drug assets, financing, and development workflows. The platform aims to streamline the drug development process using AI and blockchain technology.

DVLP Medicines | 103 followers on LinkedIn. DVLP is digital drug development. | DVLP Medicines: Building a New Infrastructure for Drug Development
At DVLP Medicines, we&#39;re building a new infrastructure for drug development on the blockchain, leveraging the power of AI and blockchain technology. We&#39;re reimagining the entire drug development process to accelerate the journey from molecule to medicine.
Our innovative platform digitizes drug assets, financing, and drug development process optimization, enabling secure, transparent, and efficient collaboration among scientists, investors, experts, regulators, and key industry players.

Jason Mauk

General Partner, DCVC

Jason Pontin

DVLP Medicines

Our CEO and Founder Jason Paragas at the NYSE representing DVLP Medicines as our dear friends at DCVC and the Super Founders Club rang the closing bell. #nyse #ourjourney #innovation #ai helping bring #medicines to #patients who need them / DVLP / 🧬🩺💡

DVLP Medicines is pleased to announce the appointment of Florencio Mazzoldi as #CTO . Florencio brings a wealth of experience in #pharmaceutical #innovation , #digitaltransformation , and strategic technology leadership to the DVLP team. With an impressive track record of driving technological advancements from notable companies such as Ginkgo Bioworks, Inc. and Autodesk , Florencio is set to play a critical role in advancing DVLP’s mission. His deep expertise in leading large-scale projects and fostering cross-functional collaborations will accelerate our efforts in delivering breakthrough treatments to market. CEO Jason Paragas commented, “Florencio’s vision and technical expertise are perfectly aligned with our goal to automate #drugdevelopment . His leadership will help us scale our capabilities and maintain our commitment to excellence.” Florencio Mazzoldi joins DVLP Medicines at a pivotal time, and we are confident that his leadership will enable us to realize the vision of "automating drug development and letting us open the first marketplace for drug development." Please join us in welcoming Florencio to the DVLP Medicines family!

We are thrilled to share that our design system, developed in collaboration with One Design Company , has been honored by Graphis Inc. The award is a testament to our commitment to technology-driven innovation in the pharmaceutical industry. Working alongside David Sieren and the team has been an incredible journey towards shaping the future of medicines with innovation, substance and durability. #pharma #drugdiscovery #pharma #aidrugdiscovery https://lnkd.in/ea-KQJ2x

At DVLP Medicines , we take a moment to remember and honor the men and women who gave their lives in service to our country. This Memorial Day, as we continue to face new challenges and technologies reshaping our world, it's important to reflect on the true meaning of this day. Let's take a moment to honor the brave individuals who made the ultimate sacrifice to defend our Nation and its ideals of freedom and liberty. Follow the link below to learn more about the history of Memorial Day. #MemorialDay #HonorTheFallen Link: https://lnkd.in/dfUKf4E

Excited to represent DVLP Medicines on the Collaboration and Success Stories panel at the Chicago Life Science Summit and the opportunity to explore the future with my long time thought partner David Sieren from One Design Company and dialog with other panel members! https://lnkd.in/eUC9R-Bp

Jason Paragas

https://lnkd.in/gpFznJwV At DVLP Medicines we are excited to put cryptography to work for operational efficiencies during the complex and costly drug development phase. A great thought piece from our partner, DCVC on practical crypto. #blockchain #drugdevelopment

Metric
Company Name	DVLP	Turbine	Ablynx	Benchling
Symbol
MSH ID	COM:DVLPMEDICINES	AI:TURBINE	COM:ABLYNX	COM:BENCHLING
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Pharmaceuticals	Biotechnology	Biotechnology	Biotechnology
Country	US	US	BE
Stage
Employee Count				501
Website	dvlpmedicines.com	turbine.ai	ablynx.com	benchling.com
LinkedIn	dvlpmedicines	turbine-ai
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		2.60K
Web Traffic Growth		0.81
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

DVLP

COM:DVLPMEDICINES

DVLP

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue